Yahoo  Jun 9  Comment 
Valeant Pharmaceuticals International Inc will pay $54 million to settle civil charges that its Salix unit paid illegal kickbacks to induce doctors to prescribe seven of its products, causing the submission of thousands of fraudulent reimbursement...
Clusterstock  Jun 9  Comment 
The U.S. government joined a whistleblower lawsuit accusing the Salix unit of Valeant Pharmaceuticals International Inc of paying illegal kickbacks to doctors to induce them to prescribe its products, and submitting false claims for the products...
FiercePharma  Jun 9  Comment 
Valeant wraps up Salix marketing probe with $54M deal--but it's far from in the clear chelfand Thu, 06/09/2016 - 11:26
FierceBiotech  Mar 24  Comment 
Atlantic Healthcare is planning to roll out the next phase of a strategy designed to establish itself as a transatlantic specialty pharma company. The move will see Atlantic open an office near Raleigh, NC, the life science hub where the former...
FierceBiotech  Mar 21  Comment 
Atlantic Healthcare has raised $24 million in its latest financing, with the founders of Salix Pharmaceuticals and Clinigen Group stumping up much of the cash and Dr. Lorin Johnson joining the company's leadership team.
Clusterstock  Mar 15  Comment 
There was a lot of weirdness on the conference call that Valeant Pharmaceuticals held on Tuesday. Analysts were combative, and there was some confusion about how much cash the company's holding. It was all made worse by a typo that – once...
Benzinga  Feb 10  Comment 
Reuters reported on Tuesday that the U.S. Securities and Exchange Commission is investigating former top executives at Salix Pharmaceuticals over allegedly misleading investors. The investigation focuses on Salix's 2014 disclosure that its...
newratings.com  Oct 1  Comment 
WASHINGTON (dpa-AFX) - Salix Animal Health LLC is voluntarily recalling one lot of "Good 'n' Fun - Beefhide Chicken Sticks" due to possible contamination with the harmful Salmonella bacteria. Packaged in a 2.8 ounce bag, the recalled...


Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing, and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. The company has a number of products currently approved for sales. These include Colazal (balsalazide disodium) for the treatment of mild to moderate active ulcerative colitis, Azasan (azathioprine) immuno-suppressive therapy for renal homo-transplant rejection and rheumatoid arthritis, and Anusol/Proctocort (hydrocortisone) for the relief of inflammatory dermatoses and hemorrhoids. In May 2004, the company received final Food and Drug Administration (FDA) approval for Xifaxan (rifaximin), an oral antibiotic for the treatment of traveler's diarrhea. Salix Pharmaceuticals is working on additional indications for Xifaxan, as well as a granulated formulation of mesalamine a common treatment option for ulcerative colitis.

Salix subsequently added new products to its portfolio including Visicol, indicated for colon cleansing prior to colonoscopy OsmoPrep, a next-generation Visicol which was launched in June 2006 and MoviPrep, a liquid bowel cleansing agent which was launched in October 2006. While Visicol and OsmoPrep were acquired by the company through its merger with InKine Pharmaceutical, exclusive U.S. in-licensing rights for MoviPrep were acquired from Norgine B.V. Recent additions to the product portfolio include Sanvar IR, indicated for the treatment of acute esophageal variceal bleeding (EVB) two hospital-based products, Pepcid Oral Suspension (indicated for several gastrointestinal indications including the treatment of duodenal ulcer, benign gastric ulcer and gastroesophageal reflux disease) and Diuril Oral Suspension (an adjunctive therapy in edema associated with several conditions including hepatic cirrhosis), from Merck and metoclopramide Zydis, indicated for short term (4 12 weeks) therapy for adults with symptomatic documented gastroesophageal reflux who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastric stasis.

Salix focuses primarily on the U.S. pharmaceutical market, promoting its drugs through its specialized sales force. Management also seeks to form strategic alliances to market its products outside the U.S. in order to avoid the significant costs, risks, and infrastructure inherent in assembling an international sales force. Salix is located in Morrisville, NC and employs roughly 240 professionals.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki